Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline. Adding Zelapar as an adjuvant to levodopa reduces the motor complications after a few hours of response to levodopa ingestion. The MAO-B enzyme primarily catalyzes the conversion of dopamine and phenylethylamine in the brain. Selegiline binds to the MAO-B enzyme site and renders it inactive to provide a longer duration of dopamine in the synapse, thereby prolonging the therapeutic effect from levodopa therapy.
Zelapar (selegiline; Valeant) has been overshadowed by the subsequent launch of Teva’s monoamine oxidase B (MAO-B) inhibitor Azilect (rasagiline), largely due to Azilect’s favorable tolerability and lack of harmful metabolites that are associated with selegiline. Zelapar was launched in the US in 2006 and has thus far generated disappointing sales. Although the novel buccal formulation showed promise for dysphagic patients, Zelapar has rapidly disappeared from the market.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.